AR060039A1 - Formulaciones novedosas - Google Patents

Formulaciones novedosas

Info

Publication number
AR060039A1
AR060039A1 ARP070101155A ARP070101155A AR060039A1 AR 060039 A1 AR060039 A1 AR 060039A1 AR P070101155 A ARP070101155 A AR P070101155A AR P070101155 A ARP070101155 A AR P070101155A AR 060039 A1 AR060039 A1 AR 060039A1
Authority
AR
Argentina
Prior art keywords
formulations
formula
biocompatible polymer
independently
biocompatible
Prior art date
Application number
ARP070101155A
Other languages
English (en)
Spanish (es)
Original Assignee
3M Innovative Properties Co
Glaxo Wellcome Mfg Pte Ltd
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38523271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 3M Innovative Properties Co, Glaxo Wellcome Mfg Pte Ltd, Glaxo Group Ltd filed Critical 3M Innovative Properties Co
Publication of AR060039A1 publication Critical patent/AR060039A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ARP070101155A 2006-03-22 2007-03-21 Formulaciones novedosas AR060039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78463406P 2006-03-22 2006-03-22

Publications (1)

Publication Number Publication Date
AR060039A1 true AR060039A1 (es) 2008-05-21

Family

ID=38523271

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101155A AR060039A1 (es) 2006-03-22 2007-03-21 Formulaciones novedosas

Country Status (18)

Country Link
EP (1) EP2012797A2 (ja)
JP (1) JP2009530419A (ja)
KR (1) KR20080110854A (ja)
CN (1) CN101415428A (ja)
AR (1) AR060039A1 (ja)
AU (1) AU2007226899A1 (ja)
BR (1) BRPI0708798A2 (ja)
CA (1) CA2646236A1 (ja)
CR (1) CR10261A (ja)
EA (1) EA200801854A1 (ja)
IL (1) IL193723A0 (ja)
MA (1) MA30328B1 (ja)
MX (1) MX2008011967A (ja)
NO (1) NO20083760L (ja)
PE (1) PE20080124A1 (ja)
TW (1) TW200803870A (ja)
WO (1) WO2007109698A2 (ja)
ZA (1) ZA200807682B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2400950T3 (pl) * 2009-02-26 2019-12-31 Glaxo Group Limited Preparaty farmaceutyczne zawierające 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzylo)oksy]etoksy}heksylo)amino]-1-hydroksyetylo}-2-(hydroksymetylo)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021229A1 (en) * 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
OA12394A (en) * 2000-08-05 2004-07-09 Glaxo Group Ltd 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent.

Also Published As

Publication number Publication date
ZA200807682B (en) 2009-11-25
EA200801854A1 (ru) 2009-04-28
MA30328B1 (fr) 2009-04-01
KR20080110854A (ko) 2008-12-19
BRPI0708798A2 (pt) 2011-06-14
AU2007226899A1 (en) 2007-09-27
IL193723A0 (en) 2009-08-03
PE20080124A1 (es) 2008-04-21
WO2007109698A2 (en) 2007-09-27
CR10261A (es) 2008-11-26
CN101415428A (zh) 2009-04-22
TW200803870A (en) 2008-01-16
NO20083760L (no) 2008-12-17
MX2008011967A (es) 2009-01-14
WO2007109698A3 (en) 2008-12-18
JP2009530419A (ja) 2009-08-27
EP2012797A2 (en) 2009-01-14
CA2646236A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
BR9916865A (pt) Composição farmacêutica em aerossol contendohfa 227 e hfa 134a
BR0303348A (pt) Formulações de aerossol para administração pulmonar de medicamentos com o intuito de produzir efeito sistêmico
BRPI0412211A (pt) composições de liberação controlada
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
WO2004108162A3 (en) Controlled release pharmaceutical composition
RS20070511A (en) Modified release pharmaceutical compositions and processes thereof
NZ588913A (en) Liver cancer drug
DE60114571D1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
PE20080765A1 (es) Formas de dosificacion farmaceutica
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
DE60104399D1 (de) Pulverformulierung zur inhalation
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
KR870000068A (ko) 경구용 약제 조성물
AR018891A1 (es) Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol
MX2007006212A (es) Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular.
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
AR066313A2 (es) Una formulacion de liberacion controlada de galantamina, una forma farmaceutica de dosificacion, un proceso para la preparacion de dicha formulacion, y el uso de dicha formulacion para la manufactura de un medicamento
ATE389389T1 (de) Mehrfach beschichete pharmazeutische dosierungsform
UY29905A1 (es) Formulación farmacéutica de absorción oral y su método de administración
TNSN02039A1 (en) RECONSTITUTABLE PARENTERAL COMPOSITION
WO2006123357A3 (en) Oral controlled release composition containing levetiracetam
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
WO2019113559A3 (en) Phenotypic markers for cell therapy and related methods

Legal Events

Date Code Title Description
FA Abandonment or withdrawal